FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience
This article was originally published in The Pink Sheet Daily
A long-time FDA veteran who remains largely unknown to the generics industry, Kathleen Uhl replaces CDER Director Janet Woodcock as acting director of the Office of Generic Drugs effective March 19 following Gregory Geba’s March 15 departure from the generic office’s top post.
You may also be interested in...
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.
Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.
Implementer of many drug review changes will leave in January after nearly 32 years of public service.